专治细胞培养的隐形杀手-- Mycoplasma ！
订货单号：3050044
规格: 5 ml (50 ug/ml)
根据报道，细胞培养过程中感染支原体的几率是30-60%不等。经支原体感染过后的细胞，其所有细胞生长参数，代谢皆会受到改变，近而影响到研究数据的准确性。
Mycoplasma Removal Agent
功能：
1. 预防细胞培养过程中支原体的感染。
2. 去处感染细胞中的支原体。
作用原理：
MRA 是 Quinoline 类的抗生素，其抑菌机制是：抑制中支原体 DNA gyrase 的功能，使其 DNA 无法复制，而达到抑制中支原体繁殖的效果。
产品特点：
1. 可有效对抗多种常见中支原体菌株。
2. 作用时间快速，一星期内立即见效。
3. Ready-to-use，只需以建议剂量加入培养液中即可。
4. 作用剂量底(0.5ug/ml)，低细胞毒性。
样品数据：
1. Data on mycoplasma removal effect - spontaneous infection.
| | | Duration of cultures (days) |
| | Concentration of MRA (ug/ml) | 0 | 7 | 14 | 21 |
| Human-derived cell-A (Human melanoma) | 0.39
0.2
0.1
0 | +
+
+
+ | -
-
-
+ | -
-
+
+ | -
-
+
+ |
| Human-derived cell-B (Human lung carcinoma) | 0.78
0.39
0.2
0.1
0 | +
+
+
+
+ | -
-
-
+
+ | -
-
-
+
+ | -
-
-
+
+ |
+ = Mycoplasma positive
- = Mycoplasma negative
Duration treated with MRA: 7 days
2. Efficacy comparison of MRA and pharmaceuticals on the market.
| | MRA | Tiamulin | Minocycline |
| | MIC* | MMC** | MIC | MMC | MIC | MMC |
| M. orale CH-19299
M. arginini G-230
M. hyorhinis BST-7
A. laidlawii PG-8 | 0.05
0.1
0.05
0.0125 | 0.1
0.2
0.1
0.025 | 0.0031
0.0063
0.0031
0.05 | 3.13
12.5
0.39
>100 | 0.05
0.2
0.0031
0.05 | 25
>100
0.39
>100 |
| MMC/MIC | 2 | 128 -------------> 2048 | 512 -------------> 2048 |
M. = Mycoplasma A. = Acholeplasma
* = Minimum inhibitory concentration (ug/ml) ** = Minimum mycoplasmacidal concentration (ug/ml)
3. MIC of MRA to other mycoplasma (ug/ml)
| Species | MIC |
| Mycoplasma fermentans PG-18
Mycoplasma salivarium PG-20
Mycoplasma hominis PG-21
Mycoplasma buccale CH-20247 | 0.0125
0.1
0.1
0.025 |
This product has been expressly manufactured by Dainippon Pharmaceutical Co., Ltd. in co-operation with MP Biomedicals, Inc.
厦门励远科技有限公司
李先生:13599215895
Email:lsh_ly@126.com
